Paul Shashi B, Manjunatha Y C, Acharya Subrat K
Department of Radiodiagnosis, All India Institute of Medical Sciences New Delhi, India.
Trop Gastroenterol. 2009 Jul-Sep;30(3):125-34.
Hepatocellular carcinoma (HCC) is a global health problem, the fifth most common cancer in the world. HCC occurs in a histologically abnormal liver due to underlying chronic liver disease resulting as a sequele of the chronic viral infections, hepatitis B and C. Since these two viral infections are endemic in Asia and Africa, more than 80% of cases are encountered in these regions. In India, a large proportion of the population is "at risk" for developing chronic liver disease and, therefore, HCC. Due to the lack of screening programmes in the country, the majority of HCC patients are diagnosed at an advanced stage of the disease, thus treatment remains a challenge. Palliative therapy forms the mainstay of treatment for this group of patients. The current era provides a plethora of options for the palliative management of HCC. This review concisely summarises the historical perspective and the current status of palliative treatment in advanced HCC.
肝细胞癌（HCC）是一个全球性的健康问题，是世界上第五大常见癌症。HCC发生于组织学上异常的肝脏，这是由慢性病毒感染（乙型和丙型肝炎）导致的潜在慢性肝病的后遗症。由于这两种病毒感染在亚洲和非洲流行，超过80%的病例出现在这些地区。在印度，很大一部分人口“有风险”发展为慢性肝病，进而发展为HCC。由于该国缺乏筛查项目，大多数HCC患者在疾病晚期才被诊断出来，因此治疗仍然是一项挑战。姑息治疗是这组患者治疗的主要手段。当前时代为HCC的姑息治疗提供了大量选择。本综述简要总结了晚期HCC姑息治疗的历史背景和现状。
